Washington Medicaid and semaglutide
Wegovy for weight loss: no. Not covered for weight loss. The policy has approval paths for heart risk with BMI 27 or higher and for a liver condition (MASH), with prior authorization. Age 20 and younger follow EPSDT rules. Ozempic for weight loss: no. State rule excludes any drug prescribed for weight loss. The GLP-1 policy requires a type 2 diabetes diagnosis or qualifying HbA1c, with prior authorization.; for type 2 diabetes Washington Medicaid must cover it. Read from Washington State Health Care Authority documents Nov 6, 2026.
Wegovy · Washington State Health Care Authority
“Semaglutide injection or tablet (Wegovy®) is not covered by Apple Health for weight loss in accordance with:”
read Nov 6, 2026
Ozempic · Washington State Health Care Authority
“Diagnosis of type 2 diabetes or an HbA1c ≥ 6.5 within the last 12 months;”
read Nov 6, 2026
In 2025 Washington Medicaid paid for 31,164 semaglutide prescriptions (Ozempic, Rybelsus, Wegovy), 28% of its GLP-1 prescriptions and 30th of the 50 states and DC. It reimbursed $29.9 million before rebates, $959 a prescription against $1,104 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Ozempic | 28,320 | $26.6 million | $939 |
| Rybelsus | 1,629 | $1.7 million | $1,042 |
| Wegovy | 1,215 | $1.6 million | $1,307 |
Washington plans and prescribing rules
Washington Public Employees Benefits Board (PEBB) program. No Washington PEBB plan covers GLP-1 drugs for weight loss, as of the Health Care Authority's February 2026 newsletter.
Premera Blue Cross. Premera Blue Cross covers weight-management GLP-1s only when an employer group elects that benefit. In 2026 it added GLP-1 Access Select, an employer option that sets a BMI threshold of 35 for weight-loss GLP-1s.



